Heart Disease in Cats: Symptoms, Causes, Diagnosis, Treatment & Prognosis

What Is Heart Disease in Cats?

The single most important thing to know: most feline heart disease is a problem of the heart muscle itself, not of the valves or coronary arteries, and cats can hide it for years before it becomes obvious. When a cat's heart muscle thickens, stiffens, or weakens, it cannot relax or fill properly between beats, so less blood moves forward with each cycle and pressure backs up behind it ^[1].

Heart disease in cats is overwhelmingly a cardiomyopathy, a disease of the heart muscle, rather than the valvular or coronary artery problems common in people ^{[1, 2, 3, 4]}. As the muscle walls thicken or stretch, they lose elasticity. The ventricles cannot fill completely during diastole (the relaxation phase), reducing the amount of blood pumped forward and causing blood to back up into the lungs or body cavities ^[1].

When the failing heart causes fluid to leak into the lungs (pulmonary edema), chest cavity (pleural effusion), or abdomen (ascites), the result is a syndrome called congestive heart failure (CHF). CHF is a pattern of signs, not a single disease, and can be triggered by several underlying conditions ^{[5, 6]}. This article defines the types and stages of feline cardiomyopathy, reviews signs and diagnostic approaches, covers established and emerging treatments, and addresses prognosis, cost, and quality-of-life decisions.

Types and Stages of Heart Disease in Cats

Takeaway: hypertrophic cardiomyopathy (HCM) is by far the most common form, affecting roughly one in seven cats, and the ACVIM staging system is the roadmap your vet uses to plan treatment. Cardiomyopathies are grouped by phenotype, meaning the visible pattern of structural change: hypertrophic (HCM), dilated (DCM), restrictive (RCM), arrhythmogenic right ventricular (ARVC), and unclassified (UCM) ^{[2, 1, 7]}.

HCM is defined by non-physiologic thickening of the left ventricle (the main pumping chamber) and impaired relaxation, known as diastolic dysfunction (the heart cannot fill properly between beats). A subset also develops dynamic obstruction of the outflow tract, called obstructive HCM or oHCM ^{[2, 7]}. HCM has a prevalence of approximately 15% in the general cat population and up to 29% in older cats ^{[8, 2, 9]}. DCM produces dilated chambers, thin walls, and weak contraction. Taurine deficiency, the classic cause, is now rare thanks to balanced commercial diets, though it still occasionally occurs ^{[10, 1]}. RCM exists in two forms: an endomyocardial form with scarring and mid-ventricular obstruction, and a myocardial form with normal wall thickness but enlarged atria ^[9]. ARVC primarily affects the right ventricle, causing dilation, arrhythmias, and right-sided failure ^{[1, 3]}. UCM is a catch-all for cardiomyopathies that don't fit other categories ^[1].

By cause, cardiomyopathies are either primary (idiopathic, often hereditary) or secondary to systemic disease, most commonly hyperthyroidism (overactive thyroid), systemic hypertension (high blood pressure), and taurine deficiency ^{[11, 1, 3, 12]}. The ACVIM staging system sorts cats by risk: Stage A (predisposed but no structural disease), Stage B1 (subclinical, low risk, normal or mildly enlarged left atrium), Stage B2 (subclinical, high risk, moderate or severe left atrial enlargement), Stage C (current or past heart failure or thromboembolism), and Stage D (refractory heart failure) ^{[3, 8, 2, 13]}. Early detection at Stage B1 or B2 is critical because it allows risk-stratified monitoring and timely thromboprophylaxis (clot-prevention medication) with clopidogrel in B2, interventions that can delay the onset of clinical signs ^{[9, 4, 10]}.

What this means for your cat: Subclinical cats (Stage B) are often asymptomatic, while cats in Stage C present with breathing difficulty, abdominal distension, or sudden hindlimb paralysis from a clot. Knowing the stage tells your vet how aggressively to treat.

First Signs and Symptoms to Watch For

Takeaway: many cats with significant heart disease show no outward signs at all, so the first recognized symptom is sometimes sudden death, which is why home monitoring matters. Cats with cardiomyopathy frequently appear completely normal until the disease is advanced, and even cats with severe structural changes can have a normal physical exam ^{[1, 7]}.

Subtle early indicators include reduced activity, hiding, a drop in appetite, and unexplained weight loss. These are easy to miss, especially in stoic indoor cats ^{[1, 5]}. Left-sided congestive heart failure produces respiratory distress: increased resting breathing rate, labored breathing, open-mouth breathing, and reluctance to lie down ^{[5, 9, 3]}. Right-sided heart failure, most typical of ARVC, leads to abdominal distension from fluid accumulation in the belly (ascites), and jugular vein distension may be seen ^{[1, 3]}.

Feline arterial thromboembolism (FATE or "saddle thrombus") presents acutely as sudden hindlimb paralysis or weakness, painful vocalization, cold paws, absent femoral pulses, and bluish nail beds, the classic "5 P's" (paralysis, pain, pulselessness, pallor, poikilothermia, meaning cold limb) ^{[1, 9]}. Additional signs may include pale or bluish gums, weak pulses, low body temperature, and fainting episodes ^{[1, 5, 3]}. Stressful events, anesthesia, surgery, or intravenous fluid administration can trigger acute decompensation in a previously stable cat ^[12].

Owners should monitor resting respiratory rate (breaths per minute while calm or sleeping) at home; a rate sustained above 30 breaths per minute demands immediate veterinary evaluation ^{[5, 1]}. When cardiomyopathy is secondary to systemic disease, cats may also show signs of the underlying condition, such as weight loss with a ravenous appetite in hyperthyroidism, or retinal hemorrhage and sudden blindness in hypertension.

Causes and Risk Factors

Takeaway: most cases are idiopathic (no identifiable cause), but in Maine Coons, Ragdolls, and Sphynx, a known genetic mutation is responsible, and secondary causes like hyperthyroidism and hypertension can be reversed if caught early. Most feline cardiomyopathies are primary (idiopathic); no systemic trigger is identified, though a genetic component is proven in certain breeds ^{[11, 3]}.

Inherited HCM has been linked to mutations in the myosin binding protein C (MYBPC3) gene in Maine Coon, Ragdoll, and Sphynx cats, and reported in some domestic shorthair families, but the majority of HCM cases have no known genetic marker ^{[3, 7]}. DCM is most famously associated with taurine deficiency from unbalanced homemade, vegetarian, or vegan diets; commercial cat foods now meet minimum taurine requirements, making dietary DCM uncommon ^{[10, 1, 3]}. Secondary left ventricular (LV) hypertrophy and cardiomyopathy can develop from chronic systemic hypertension (often driven by kidney disease), hyperthyroidism, acromegaly (excess growth hormone), and aortic stenosis (narrowing of the aortic valve) ^{[12, 8]}.

Transient myocardial thickening is a reversible form of LV hypertrophy triggered by dehydration, stress, inflammation, or recent anesthesia; it usually resolves once the inciting factor is corrected ^{[3, 11]}. Male sex and middle-to-older age (mean around 6 years, range 6 months to 16 years) are risk factors for HCM ^{[9, 7]}. Breeds at increased risk include Maine Coon, Ragdoll, Persian, Sphynx, British Shorthair, Norwegian Forest, Siberian, Turkish Van, Himalayan, and Birman ^{[9, 7]}. Cats belonging to predisposed breeds (Stage A) benefit from regular echocardiographic screening (ultrasound of the heart) even without a murmur ^{[2, 3]}. When cardiomyopathy is secondary to hyperthyroidism, hypertension, or taurine deficiency, treating the underlying disorder can result in partial or complete reversal of cardiac changes.

How Vets Diagnose Heart Disease in Cats

Takeaway: echocardiography is the gold-standard test, and the absence of a heart murmur does NOT rule out heart disease. A thorough physical examination may detect murmurs, gallop rhythms (extra heart sounds suggesting stiff or overloaded ventricles), or arrhythmias (abnormal heart rhythms), but many affected cats have normal auscultation (listening with a stethoscope), so the absence of a murmur does not exclude cardiomyopathy ^{[10, 1]}.

Accurate blood pressure measurement is essential to identify systemic hypertension, which can cause or worsen cardiac changes ^{[5, 11]}. Thoracic radiographs (chest X-rays) evaluate heart size, left atrial enlargement, and signs of congestive heart failure such as pulmonary edema or pleural effusion ^{[5, 10, 9]}. Echocardiography (cardiac ultrasound) is the gold standard; it quantifies LV wall thickness, left atrial size, systolic function (the heart's contracting ability), outflow tract obstruction, and risk markers for thromboembolism such as spontaneous echo contrast ("smoke" in the left atrium that signals blood stasis and clot risk) ^{[1, 10, 8]}. ACVIM staging relies heavily on echocardiography: normal or mildly enlarged left atrium defines B1, moderate-to-severe enlargement defines B2, and Stage C is assigned once CHF or a clot event has occurred ^{[2, 3, 13]}.

Electrocardiography (ECG) detects arrhythmias and may indicate chamber enlargement ^{[5, 1, 10]}. Cardiac biomarkers (blood substances that rise when the heart is under stress or damaged) aid screening: feline-specific NT-proBNP helps differentiate moderate-to-severe subclinical cardiomyopathy from normal or mild disease, and cardiac troponin I can help distinguish cardiac from non-cardiac causes of respiratory distress ^{[1, 4, 7]}. Genetic tests are available for known MYBPC3 mutations in Maine Coons and Ragdolls; they are most useful for breeding decisions rather than individual disease prediction ^{[7, 1, 4]}. Blood taurine levels are measured when DCM is suspected ^{[10, 1]}.

A clinical diagnosis of arterial thromboembolism is often based on the classic "5 P's" presentation; echocardiography then confirms underlying cardiomyopathy and identifies left atrial thrombus or spontaneous echo contrast ^{[10, 9]}. Screening of at-risk breeds and cats with chronic kidney disease or hypertension is recommended because early diagnosis allows thromboprophylaxis and rhythm monitoring that can prolong the preclinical phase ^{[3, 8, 10]}. The work-up must systematically rule out conditions that mimic primary cardiomyopathy, such as hyperthyroidism, hypertension, and primary pulmonary disease ^[11].

Treatment Options for Cats With Heart Disease

Takeaway: there is no cure for primary cardiomyopathy, but well-planned therapy can extend comfortable life by months to years, and the strategy is dictated by ACVIM stage and the type of cardiomyopathy. Therapy is guided by stage, clinical signs, and cardiomyopathy type; the primary goals are to control congestive signs, prevent thromboembolism, and preserve quality of life ^[4].

Stage A cats (predisposed, no structural disease) require no medication; annual echocardiographic monitoring is recommended ^{[2, 3]}. Stage B1 cats (subclinical, low risk) generally receive no proven disease-modifying drugs (medications that slow or reverse the underlying disease process); atenolol (a beta-blocker that slows heart rate and reduces outflow obstruction) may be considered if severe dynamic left ventricular outflow obstruction is present ^{[4, 7]}. Stage B2 cats (subclinical, high risk) should receive clopidogrel to reduce clot risk; supplementary antiplatelet or factor Xa inhibitor (a newer class of anticoagulants targeting a key clotting protein) therapy is reserved for very high-risk situations ^{[9, 4, 2]}.

Acute management of Stage C CHF focuses on stabilization: oxygen, cage rest to minimize stress, injectable furosemide (a loop diuretic that removes fluid from the lungs), and thoracocentesis (needle drainage of chest fluid) if significant pleural effusion is present. Intravenous fluid therapy is contraindicated ^{[5, 6, 7, 9]}. Chronic Stage C therapy combines oral furosemide, an ACE inhibitor (a blood-pressure-lowering drug that reduces the heart's workload; examples include enalapril and benazepril), and pimobendan (a drug that strengthens heart contractions and dilates blood vessels, particularly useful when systolic function is impaired). Clopidogrel is continued for thromboprophylaxis. Beta-blockers are contraindicated during uncontrolled CHF but may be reintroduced after stabilization if needed for outflow obstruction or arrhythmias ^{[4, 7, 6, 10, 9]}.

Taurine-deficient DCM is treated with taurine supplementation and a transition to a nutritionally complete, taurine-replete diet; contractility often improves ^{[10, 1, 3]}. When cardiomyopathy is secondary to hyperthyroidism, hypertension, or acromegaly, treating the primary disease can stabilize and partially reverse cardiac remodeling; hypertension is controlled with amlodipine or telmisartan, and hyperthyroidism with methimazole, radioiodine, or thyroidectomy ^[10]. Cats with concurrent chronic kidney disease require delicate balancing: furosemide doses must be titrated (carefully adjusted up or down) to control edema while avoiding dehydration and azotemia (buildup of waste products in the blood due to declining kidney function); regular monitoring of renal values and hydration is essential ^[8].

Nutritional management includes a balanced, low-sodium diet (such as veterinary therapeutic renal or cardiac formulas) that meets taurine requirements; maintaining ideal body weight is encouraged ^{[1, 10, 5]}. Management of acute arterial thromboembolism focuses on pain control, oxygen supplementation, diuretics if CHF is present, and thromboprophylaxis; prognosis is often poor, and many owners elect euthanasia ^{[14, 3, 6]}. For Stage D cats (refractory CHF), options include intensifying diuretic therapy with torsemide or adding hydrochlorothiazide, alongside pimobendan; more frequent monitoring and a shift toward palliative goals focused on comfort are essential ^{[4, 7]}.

New and Emerging Treatments for Feline Heart Disease

Takeaway: for the first time in decades, a new FDA conditionally approved drug (Felycin-CA1, a delayed-release form of rapamycin) can actually slow the progression of subclinical HCM rather than only manage its symptoms. A new generation of therapies aims to slow or halt disease progression, representing a major shift in feline cardiology ^[15].

Felycin-CA1 (delayed-release rapamycin, also called sirolimus) has received FDA conditional approval for the management of left ventricular hypertrophy in cats with subclinical HCM. The RAPACAT trial demonstrated a reduction in LV wall thickness compared to placebo ^{[15, 2, 16, 17, 18]}. Rapamycin modulates the mTOR signaling pathway (a cellular pathway that regulates growth and metabolism), reducing myocardial fibrosis (scarring of heart muscle) and pathologic hypertrophy (abnormal thickening); it is the first therapy to show direct disease-modifying potential in feline HCM ^{[7, 2]}.

Felycin-CA1 is intended for early-stage cats (B1/B2); it is not a cure and should be avoided in cats with uncontrolled diabetes or markedly elevated liver enzymes. Continued monitoring is essential ^{[2, 17]}. The HALT HCM Study, a large multicenter clinical trial, is currently underway to generate further evidence for rapamycin's efficacy and safety in feline HCM ^{[2, 18]}. Cardiac myosin inhibitors (mavacamten, aficamten) decrease sarcomere overactivation (over-contraction of the heart's contractile units) and are effective for human HCM; pharmacological activity has been demonstrated in cats, but feline-specific chronic safety and efficacy trials are incomplete ^{[7, 2]}. A cardiac myosin activator (CK-136, danicamtiv) is under investigation as a means of augmenting myocardial contractility in heart failure, though feline data are still preliminary ^[7].

While these innovations offer hope, long-term outcomes, optimal patient selection, and real-world safety profiles remain active areas of investigation; veterinarians should stay updated as evidence evolves ^{[17, 2]}.

Living With and Managing Heart Disease Long-Term

Takeaway: long-term stability depends on daily home monitoring, strict medication compliance, dietary control, and a calm environment, with the resting respiratory rate being the single most useful number an owner can track. Successful long-term management hinges on these pillars ^{[10, 5]}.

Owners should record resting respiratory rate daily using a smartphone app (e.g., Pet Breath Counter) and seek immediate care if the rate exceeds 30 breaths per minute ^{[5, 1]}. Medications must be given exactly as prescribed; never discontinue or alter doses without veterinary guidance. Many cats require tablets multiple times daily, which can be challenging but is essential for stability ^{[1, 6]}. Feed a nutritionally complete, low-sodium diet that meets taurine requirements; avoid raw, unbalanced homemade, or high-salt treats ^{[1, 10, 5]}.

Maintain a calm, predictable environment: provide hiding spots, use synthetic feline pheromones (such as Feliway, which release calming scent signals), and minimize loud noises or sudden changes. Stress can trigger decompensation ^{[1, 12]}. Schedule recheck examinations every 3–6 months, including blood pressure, blood chemistry, and periodic echocardiography ^{[10, 6]}. In cats with both heart and kidney disease, avoid overly aggressive fluid administration and adjust diuretics carefully ^[8].

Create an emergency plan: know the location of the nearest 24-hour veterinary facility, recognize signs of acute CHF or thromboembolism, and discuss advance decisions with the veterinary team ahead of time ^[6]. Keep cats indoors only and avoid strenuous activity such as prolonged laser-pointer chasing; gentle interactive play is acceptable if the cat remains comfortable ^[10]. Elective procedures in cats with cardiac disease should be postponed when the patient is unstable, and any necessary procedures require peri-procedural planning with a cardiologist.

Prognosis, Complications, and Life Expectancy

Takeaway: subclinical HCM often carries a good long-term outlook, but once CHF or a clot occurs, the prognosis becomes guarded, and outcome depends heavily on stage, type, and treatment response. Prognosis is highly variable and depends on cardiomyopathy type, ACVIM stage, left atrial size, presence of CHF or arterial thromboembolism (ATE), and response to treatment ^{[19, 3, 9]}.

Cats with subclinical HCM (Stage B1/B2) have relatively low short-term cardiac mortality: approximately 7% die of cardiovascular causes within one year of diagnosis; 5- and 10-year cardiac mortality rates are 23% and 28%, respectively ^[3]. Once a cat reaches Stage C, prognosis becomes guarded; median survival times vary widely, with some cats living 6–12 months and others surviving 1–3 years or longer before refractory disease or sudden death ^{[10, 5]}.

Arterial thromboembolism is a devastating complication: 10–20% of HCM cats develop a clot; among those that survive the acute event, the average time to a recurrent episode of CHF or ATE is 2–6 months, and many require euthanasia ^{[10, 20]}. Sudden cardiac death can occur at any stage, most commonly in cats with severe structural disease, marked atrial enlargement, or documented ventricular arrhythmias ^{[7, 12]}. Taurine-responsive DCM carries a good prognosis with appropriate diet and supplementation; non-taurine-responsive DCM is much more guarded, with survival of only weeks to months ^[10].

Cats with restrictive cardiomyopathy often present in congestive heart failure and are at high risk of thromboembolism, worsening heart failure, and sudden death; arrhythmogenic right ventricular cardiomyopathy typically carries a poor outcome due to refractory arrhythmias or heart failure ^[10]. Transient myocardial thickening is a notable exception: if the cat survives the acute event and the trigger is removed, LV wall thickness often normalizes, and long-term prognosis is excellent ^{[3, 11]}.

Negative prognostic indicators include a gallop rhythm, significant arrhythmias, marked left atrial enlargement, hypothermia at presentation, and concurrent chronic kidney disease ^{[19, 9]}. Long-term complications include recurrent CHF, progressive azotemia from diuretic therapy, new thromboembolic events, and eventual refractoriness to standard therapy (Stage D) ^{[8, 12, 6]}.

Cost of Treating Heart Disease in Cats

Takeaway: managing feline heart disease is a significant financial commitment, and pet insurance purchased before diagnosis offers the best protection against major costs. Costs arise from advanced diagnostic tests, multiple daily medications, and frequent follow-up examinations.

An initial diagnostic work-up including echocardiography, thoracic radiographs, a comprehensive blood panel, blood pressure measurement, and possibly NT-proBNP testing can easily exceed several hundred dollars, with exact figures varying by region and clinic. Monthly medication expenses for standard CHF therapy (furosemide, an ACE inhibitor, clopidogrel, and pimobendan) range from moderate to high depending on drug selection and regional pricing. Routine monitoring (blood chemistry, blood pressure, echocardiography every 6–12 months) adds ongoing annual expenses ^{[10, 6]}.

Emergency hospitalization for acute CHF or arterial thromboembolism can cost thousands of dollars per episode, underscoring the financial impact of decompensation ^[6]. Pet insurance may help offset treatment costs if purchased before diagnosis, but owners must carefully review policy terms regarding pre-existing conditions and cardiac care coverage. Open conversations about financial limitations and treatment options enable the veterinary team to tailor a plan that balances medical benefit with owner resources ^[6].

Quality of Life and End-of-Life Decisions

Takeaway: CHF is often a waxing-and-waning disease, and planning euthanasia criteria in advance prevents crisis-driven decisions and protects the cat's welfare. Cats with stable CHF can experience good days where they eat, groom, and interact, but the episodic nature of decompensation creates emotional and physical strain for both cat and owner ^[6].

The waxing-waning pattern means owners often face the difficult choice between saying goodbye while the cat is comfortable or waiting for the next crisis, which may happen when the clinic is closed or the cat is in severe distress ^[6]. Developing an advance care plan with the veterinary team, covering hospitalization, fluid drainage, medication feasibility, and objective euthanasia criteria, can prevent crisis-driven decisions ^[6].

Signs that euthanasia should be considered include:

• Recurrent respiratory distress episodes despite optimal therapy
• Frequent or severe arterial thromboembolic events
• Intractable pain
• Inability to maintain hydration or nutrition
• Progressive azotemia unresponsive to diuretic adjustments ^[6]

Owner fatigue and fear of leaving the cat alone are legitimate reasons to discuss euthanasia; when the caregiver can no longer provide required monitoring or fears a traumatic event, humane euthanasia may be the kindest path ^[6]. In-home euthanasia is a valuable option that allows cats to pass peacefully in familiar surroundings; planning ahead minimises last-minute stress ^[6]. Quality-of-life assessment tools such as the HHHHHMM scale (Hurt, Hunger, Hydration, Hygiene, Happiness, Mobility, More good days than bad) can help owners objectively assess their cat's well-being and guide end-of-life decisions. The veterinarian's role is to provide a non-judgmental, empathetic environment where owners feel supported in prioritizing their cat's comfort and dignity ^[6].

Similar Conditions That Can Look Like Cardiac Disease

Takeaway: a heart murmur does not equal heart disease, and many conditions mimic cardiomyopathy, so a thorough work-up is essential before committing to a diagnosis. Respiratory distress mimicking CHF can be caused by primary lung diseases (feline asthma, chronic bronchitis, pneumonia, pulmonary neoplasia) or pleural space diseases (pyothorax, chylothorax) ^{[7, 11]}.

Chronic anemia can cause weakness, lethargy, pale mucous membranes, and a prominent heart murmur that may be mistaken for primary heart disease, and it can also lead to or worsen cardiomegaly (enlarged heart) and heart failure. Acute hindlimb paralysis due to aortic thromboembolism must be distinguished from other causes: intervertebral disc disease, traumatic spinal injury, neoplasia, and fibrocartilaginous embolism. The "5 P's" and echocardiographic findings are key differentiators ^{[10, 9]}.

A heart murmur does not equal structural heart disease; between 25% and 69% of cats with murmurs have no echocardiographic evidence of cardiomyopathy, representing functional or flow murmurs (innocent sounds caused by normal blood flow, not by disease) ^[7]. Left ventricular hypertrophy on echocardiography is not always primary HCM; secondary LVH can be caused by systemic hypertension, hyperthyroidism, acromegaly, aortic stenosis, and transient myocardial thickening due to dehydration, stress, or anesthesia. Pseudo-hypertrophy from hypovolemia (low blood volume) and rare infiltrative diseases also occur ^{[12, 11]}.

A systematic work-up, including blood pressure, T4 (thyroid hormone level), thoracic imaging, biomarker testing, and echocardiography, is required to differentiate primary HCM from these mimics, because treatment and prognosis differ markedly ^{[1, 11, 7]}. Cats with hyperthyroidism often present with weight loss and a good appetite and may develop a secondary cardiomyopathy; successful treatment of the thyroid condition can result in significant improvement of the heart changes, confirming the secondary nature ^[10].

What We Still Don't Know: Gaps and Current Research

Takeaway: research is actively reshaping feline cardiology, but many questions remain about genetics, optimal thromboprophylaxis, the interaction between heart and kidney disease, and the long-term value of new therapies. The cause of most feline cardiomyopathies, especially HCM in non-pedigree cats, remains unknown; beyond the few breed-specific mutations, the underlying genetic and environmental triggers are poorly defined ^[3].

Evidence for antithrombotic prevention is very limited: only three small studies have examined prophylactic strategies for ATE in at-risk cats; optimal drug selection, dosing, and duration are still unclear ^[14]. There is a critical lack of evidence-based guidelines for managing cats with concurrent moderate-to-advanced kidney disease and heart failure; recommended drug doses and diuretic strategies are often extrapolated from healthier populations, leading to potential under-treatment or over-treatment ^[8].

While delayed-release rapamycin and myosin inhibitors show promise, long-term safety, efficacy in preventing CHF or ATE, and optimal patient-selection criteria remain under investigation in large-scale trials (e.g., HALT HCM) ^{[2, 18]}. Transient myocardial thickening is a fascinating but poorly understood phenomenon; its triggers, molecular pathways, and true recurrence rates need prospective study ^{[3, 11]}.

No pathognomonic (uniquely diagnostic) cardiac biomarker exists, and the clinical utility of existing biomarkers (e.g., NT-proBNP, cardiac troponin I) for early detection of subclinical HCM remains uncertain; ongoing research aims to develop sensitive, accessible point-of-care biomarker panels to facilitate broader screening. The contribution of myocardial ischemia (reduced blood flow to the heart muscle), microvascular dysfunction, and ventricular arrhythmias to disease progression and sudden death is understudied in cats, representing an important area for future research ^{[2, 7]}.

❓ Frequently Asked Questions